RT Journal Article
SR Electronic
T1 Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.17.21263532
DO 10.1101/2021.09.17.21263532
A1 Tauzin, Alexandra
A1 Gong, Shang Yu
A1 Beaudoin-Bussières, Guillaume
A1 Vézina, Dani
A1 Gasser, Romain
A1 Nault, Lauriane
A1 Marchitto, Lorie
A1 Benlarbi, Mehdi
A1 Chatterjee, Debashree
A1 Nayrac, Manon
A1 Laumaea, Annemarie
A1 Prévost, Jérémie
A1 Boutin, Marianne
A1 Sannier, Gérémy
A1 Nicolas, Alexandre
A1 Bourassa, Catherine
A1 Gendron-Lepage, Gabrielle
A1 Medjahed, Halima
A1 Goyette, Guillaume
A1 Bo, Yuxia
A1 Perreault, Josée
A1 Gokool, Laurie
A1 Morrisseau, Chantal
A1 Arlotto, Pascale
A1 Bazin, Renée
A1 Dubé, Mathieu
A1 De Serres, Gaston
A1 Brousseau, Nicholas
A1 Richard, Jonathan
A1 Rovito, Roberta
A1 Côté, Marceline
A1 Tremblay, Cécile
A1 Marchetti, Giulia C.
A1 Duerr, Ralf
A1 Martel-Laferrière, Valérie
A1 Kaufmann, Daniel E.
A1 Finzi, Andrés
YR 2021
UL http://medrxiv.org/content/early/2021/11/10/2021.09.17.21263532.abstract
AB While the standard regimen of the BNT162b2 mRNA vaccine includes two doses administered three weeks apart, some public health authorities decided to space them, raising concerns about vaccine efficacy. Here, we analyzed longitudinal humoral responses including antibody binding, Fc-mediated effector functions and neutralizing activity against the D614G strain but also variants of concern and SARS-CoV-1 in a cohort of SARS-CoV-2 naïve and previously infected individuals, with an interval of sixteen weeks between the two doses. While the administration of a second dose to previously infected individuals did not significantly improve humoral responses, we observed a significant increase of humoral responses in naïve individuals after the 16-weeks delayed second shot, achieving similar levels as in previously infected individuals. We compared these responses to those elicited in individuals receiving a short (4-weeks) dose interval. For the naïve donors, these responses were superior to those elicited by the short dose interval.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by le Ministere de l Economie et de l Innovation du Quebec, Programme de soutien aux organismes de recherche et d innovation to A.F. and by the Fondation du CHUM. This work was also supported by a CIHR foundation grant #352417, by a CIHR operating Pandemic and Health Emergencies Research grant #177958, a CIHR stream 1 and 2 for SARS-CoV-2 Variant Research to A.F., and by an Exceptional Fund COVID-19 from the Canada Foundation for Innovation (CFI) #41027 to A.F. and D.E.K. Work on variants presented was also supported by the Sentinelle COVID Quebec network led by the LSPQ in collaboration with Fonds de Recherche du Quebec Sante (FRQS) to A.F. This work was also partially supported by a CIHR COVID-19 rapid response grant (OV3 170632) and CIHR stream 1 SARS-CoV-2 Variant Research to MC. Plasma Donor Biobank at Hema-Quebec was supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force. A.F. is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. MC is a Tier II Canada Research Chair in Molecular Virology and Antiviral Therapeutics. V.M.L. is supported by a FRQS Junior 1 salary award. D.E.K. is a FRQS Merit Research Scholar. G.B.B. is the recipient of a FRQS PhD fellowship and J.P. is the recipient of a CIHR PhD fellowship. G.S. is supported by a scholarship from the Department of Microbiologie, Infectiologie et Immunology of Universite de Montreal. R.G. and A.L. were supported by MITACS Acceleration postdoctoral fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We declare no competing interests.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All work was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate institutional board. Blood samples were obtained from donors who consented to participate in this research project at Centre Hospitalier de l Universite de Montreal (CHUM) and in the Plasma Donor Biobank at Hema-Quebec. The study was approved by the respective Institutional Review Boards (no. 19.381 at CHUM and no. REB-B-6-002-2021-003 at Hema-Quebec).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis article includes all datasets generated and analyzed for this study. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Author (andres.finzi{at}umontreal.ca).